The Institut Bordet Medical Oncology Clinic has a number of roles:
- diagnosis and therapeutic care of patients with solid tumours
- overseeing administration of cancer medication for in-patients and out-patients
- monitoring patients during and after their treatment.
The Clinic takes a multidisciplinary approach. Therapeutic decisions are made in consultation with other specialist doctors and healthcare professionals involved in the patient’s care.
The aim is that patients should be monitored in all respects, including psychologically.
The Medical Oncology Clinic forms an integral part of the Department of Oncological Medicine. It is also very active in clinical research (particularly in the development of new medication) and translational research. At the Clinic, research is integrated into the care provided, enabling patients to benefit from the latest diagnostic and therapeutic advances, well before these become part of clinical routine.
The Medical Oncology Clinic is divided into 12 sectors:
- thoracic oncology
- urogenital oncology
- breast oncology
- innovative treatments
- endocrine tumour oncology
- bone and soft tissue tumour oncology
- gynaecological oncology
- digestive oncology
- cervico-facial oncology
- skin tumour oncology
- oncogeriatrics
- central nervous system oncology.
The Medical Oncology Clinic works in close collaboration with the Institut Bordet Clinical Trials Conduct Unit (CTCU). This unit, which is responsible for the development of new drugs and innovative approaches to care, handles phase I, II and III clinical studies in tumours. The CTCU is made up of research nurses, clinical research associates and data managers who, with research doctors, closely monitor patients taking part in clinical trials.
The Institut’s different research laboratories are also closely linked to the Medical Oncology Clinic. Their principal aim is to identify predictive marker molecules (indicating probability of response to a given treatment) and/or prognosis (chances of a cure) as part of the development of breast cancer treatments.
The Medical Oncology Clinic participates actively in research projects conducted by many international collaborative groups such as the EORTC and the Breast International Group (BIG).
Recently, the Oncodistinct research network was created. This network brings together numerous researchers who share a common vision of innovative clinical research. The aim of the network is to accelerate the personalisation of treatment and the development of innovative treatments while also promoting a multidisciplinary approach to research and care.
Below, among others, some studies :
- BRAINSTORM
- ROSALINE
- TENACITY
- Destiny Pan-Tumor 01
- Futibatinib
- GeNeo
The Institut Bordet Medical Oncology Clinic plays an important role in education, both in Belgium and abroad. Within the hospital, the Clinic’s medical team supervises the training of young doctors and medical students specialising in oncology. Always keen to promote quality training, the Clinic also welcomes many doctors from abroad as part of its Fellowship Programme.
Research projects
Project 1
AURORA Programme aimed at understanding the molecular characteristics of recurrent and metastatic breast cancer early in the evolution of metastatic disease.
- Project leaders : Philippe Aftimos, Martine Piccart
- Collaborations : International clinical study (80 partners)
- Funding (or) Support : BIG
Project 2
CHARACTERIZATION OF ENDOCRINE RESISTANT Luminal Breast Cancer using spatial transcriptomics AND epigenetic ANALYSIS.
- Project leaders : Christos Sotiriou, Françoise Rothé and Mattia Rediti
- Collaborations :
- Dr François Fuks, Laboratory of Cancer Epigenetics, ULB-Cancer Research Center (U-CRC), Université libre de Bruxelles
- Prof Lundeberg at the SciLife laboratory, Stockholm, Sweden
- Dr Frédérick Libert, ULB/VUB Brightcore sequencing facility
Project 3
ZENITH: A PHASE 2 STUDY OF ZEN003694 IN COMBINATION WITH TALAZOPARIB IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER (BRCA1 OR BRCA2 NON MUTATED)
- Project leader : Philippe Aftimos
- Collaborations : International clinical study
- Funding (or) Support : Zenith Epigenetics Ltd.
Project 4
MULTICENTRIC PHASE II SINGLE-ARM STUDY OF NIVOLUMAB IN PATIENTS WITH TYPE B3 THYMOMA AND THYMIC CARCINOMA PREVIOUSLY TREATED WITH CHEMOTHERAPY
- Project leader : Thierry Berghmans
- Collaborations : International clinical study
- Funding (or) Support : EORTC
Project 5
AURA : Avelumab as neoadjuvant therapy in subjects with urothelial muscle invasive bladder cancers
- Project leader : Nieves Martinez-Chanza, Ahmad Awada
- Collaborations : Oncodistinct - CTSU
Our team
Head of the Medical Oncology Clinic
Pr A. Awada
Solid Tumours / New Innovative drugs
Pr A. Awada, Dr Ph. Aftimos, Dr N. Kotecki
Solid and RareTumours
Pr A. Awada, Dr Ch. Jungels
Breast Oncology
Pr M. Piccart, Dr D. de Valeriola
Dr Ph. Aftimos, Dr A. Gombos
Pr Ch. Sotiriou, Dr E. de Azambuja
Dr M. Ignatiadis, Dr F. Lebrun
Dr L. Buisseret, Dr L. Polastro
Pr A. Drowart, Dr D. t’Kint de Roodenbeke
Dr M. Hanappe
Oncogeriatrics
Dr L. Dal Lago, Dr L. Dumont (geriatrician)
Cervico-facial Oncology
Dr Y. Lalami, Dr S. Luce
Skin Tumour Oncology
Pr A. Awada, Pr A. Drowart, Dr M. Langouo
Dr M. Suppa (dermatologue)
Digestive Oncology / Gastroenterology / Endoscopy
Dr A. Hendlisz, Dr F. Sclafani
Dr R. Saude Conde, Dr G. Bregni
Gynaecological Oncology
Dr L. Polastro, Dr F. Lebrun
Dr M. Langouo, Dr M. Hanappe
Thoracic Oncology
Pr Th. Berghmans, Dr M. Brandao
Dr Z. Mekinda
Urogenital, Bone and Soft Tissue Oncology
Dr Th. Gil, Dr Ch. Jungels (sarcomas)
Dr N. Martínez-Chanza (urogenital tumors)
Dr S. Sideris (urogenital tumors)
Oncological Day Hospital
Dr D. de Valeriola, Dr Y. Lalami, Dr L. Polastro
Oncogenetics
Dr D. t’Kint de Roodenbeke
Neuro-oncology
Dr S. Luce
Psychooncology
Pr D. Razavi
Supportive and Palliative Cares / Pain Clinic
Dr I. Libert, Dr. V. Ligabo
Consultants :
Pr J. Klastersky (internal medicine/oncology)
Dr A. Deleporte (digestive oncology)
Pr B. Desmarez (gastroenterology/endoscopy)
Dr Z. El Ali (medical oncology)
Dr J. Kerger (oncologie gynécologique/cutanée)
Dr D. Levacq (medical oncology/oncogenetics)
Dr A. Lepida (gastroenterology/hepatology)
Dr H. Louis (gastroenterology/digestive functional disorders)
Dr F. Mana (gastroenterology/endoscopy)
Dr L. Mans (digestive oncology)
Dr H. Rouvière (geriatry)
Pr A. Van Gossum (endoscopy/gastroenterology/nutrition)
Dr Y. Wissam (medical oncology)
21/04/2022
Scientific publications
Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer.
Authors : Loi S, Salgado R, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Drubay D, Lemonnier J, Sotiriou C, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, André F, Denkert C, Piccart-Gebhart M, Roblin E, Michiels S
Year : 2022
Journal : NPJ Breast Cancer
Volume : 8
Pages : 3
First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumours.
Authors : Schöffski P, Awada A, de la Bigne AM, Felloussi Z, Burbridge M, Cantero F, Colombo R, Maruzzelli S, Ammattatelli K, de Jonge M, Aftimos P, Dumez H, Sleijfer S
Year : 2022
Journal : Eur J Cancer
Volume : 169
Pages : 135-145
JCOG0603: Are We Really Sure This Was a Negative Trial?
Authors : Saude Conde R, Bregni G, Saad E, Hendlisz A, Sclafani F
Year : 2022
Journal : J Clin Oncol
Volume : 40
Pages : 803-805
Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study.
Authors : Subbiah V, Braña I, Longhi A, Boni V, Delord JP, Awada A, Boudou-Rouquette P, Sarantopoulos J, Shapiro GI, Elias A, Ratan R, Fernandez C, Kahatt C, Cullell-Young M, Siguero M, Zeaiter A, Chawla SP
Year : 2022
Journal : Clin Cancer Res
Volume : 28
Pages : 2762-2770
Knowledge, Practice, and Attitudes of Physicians in Low- and Middle-Income Countries on Fertility and Pregnancy-Related Issues in Young Women With Breast Cancer.
Authors : Khan SZ, Arecco L, Villarreal-Garza C, Sirohi B, Ponde NF, Habeeb B, Brandão M, Azim HA Jr, Chowdhury AR, Bozovic-Spasojevic I, Kovalenko I, Odhiambo A, Seid FU, Mutombo AB, Petracci F, Vidra R, Altuna SC, Petrova M, Kourie HR, Ozturk MA, Razeti MG, Lengyel CG, Talibova N, Mariamidze E, Sacardo KP, Duma N, Gyawali B, Trapani D, Tagliamento M, Lambertini M
Year : 2022
Journal : JCO Glob Oncol
Volume : 8
Pages : e2100153